Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Comment by Francine01on Jan 06, 2020 12:39pm
212 Views
Post# 30522425

RE:So what does everyone think the odds o success are?

RE:So what does everyone think the odds o success are? Hey TO, during the WE I was a bit preocupied by the effect of 12 weeks vs 8 weeks (As per COLT) and HTG vs MTG effects. 

As per TRIFCTA study (Acasti Presentation P. 37), (not signigicant), but still a very good indication. HTG (500mg/dl-800mg/dl) vs actual Ph3 T1 (500mg/d;-1500mg/dl) 1gr (N=10) and 2gr (N=14) had % vs placebo of 18% and and 19%.

As per those results, I don't see why would not reach 20% with 4 gr with higher population (mg/dl). 

I think they want to close the lag between T1 and T2 results (end of month) to avoid a sell off and profit taking. Also, by delaying theT1 results its closing the gap with HbA1C March release.

I think, they will PR T1 results between Jan 8 and Jan 15, Monday Jan 13th before opening is the most likely. They will also PR the T2 last patient visit in the same press release.

SP is probably down because 1) delay/uncertainty 2) ATM buyers are sellers and 3) its seems that some warrants were excercised late december, they are probably sellers.

GLTA!


<< Previous
Bullboard Posts
Next >>